<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31112020</article-id><article-id pub-id-type="pmc">6852464</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Profiles and Predictive Values of Interleukin-6 in Aortic Dissection:
a Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1773-2959</contrib-id><name><surname>Yuan</surname><given-names>Shi-Min</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role><role>PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Cardiothoracic Surgery, The First Hospital of Putian,
Teaching Hospital, Fujian Medical University, Putian, Fujian Province, People's
Republic of China.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Shi-Min Yuan</bold>, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-1773-2959">https://orcid.org/0000-0002-1773-2959</ext-link>, Department of
Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian
Medical University, 389 Longdejing Street, Chengxiang District, Putian, Fujian
Province, People&#x02019;s Republic of China. Zip Code: 351100. E-mail:
<email>shiminyuan@126.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2019</year></pub-date><volume>34</volume><issue>5</issue><fpage>596</fpage><lpage>604</lpage><history><date date-type="received"><day>15</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Aortic dissection (AD) has been recognized to be associated with an inflammatory
process. Clinical observations demonstrated that patients with AD had an
elevated interleukin (IL)-6 level in comparison to hypertensive or healthy
controls. Adverse events such as acute lung injury, postimplantation syndrome,
and death are associated with an elevated IL-6 level. Thus, circulating IL-6
could be a reliable biomarker for the diagnosis of AD and for the eveluation of
the therapeutic outcomes and the prognosis of AD patients. Therapeutic
interventions aiming at attenuating the inflammatory status by IL-6
neutralization could effectively decrease the IL-6 level and thus reverse the
progression of the disorder of AD patient. Endovascular aortic repair can
effectively control the inflammatory cytokines. Selective antegrade cerebral
perfusion with deep hypothermic circulatory arrest during aortic arch
replacement shows better neuroprotectve effect with an improved IL-6 level of
the cerebrospinal fluid. These results facilitate the understanding of the
etiology of AD and guide the directions for the treatment of acute AD in the
future. More effective therapeutic agents developed based on the theories of
IL-6 signaling involved in the mechasims of AD are anticipated.</p></abstract><kwd-group><kwd>Aneurysm, Dissecting</kwd><kwd>Inflammation</kwd><kwd>Interleukin-6</kwd></kwd-group></article-meta></front><body><table-wrap id="t1" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr style="background-color:#e6e7e8"><td align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</td></tr></thead><tbody><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">AAD</td><td align="left" rowspan="1" colspan="1">= Acute aortic dissection</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">= Aortic dissection</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">ALI</td><td align="left" rowspan="1" colspan="1">= Acute lung injury</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">CAD</td><td align="left" rowspan="1" colspan="1">= Chronic aortic dissection</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">DHCA</td><td align="left" rowspan="1" colspan="1">= Deep hypothermic circulatory arrest</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">= Enzyme linked immunosorbent assay</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">HTN</td><td align="left" rowspan="1" colspan="1">= Hypertension</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">IL</td><td align="left" rowspan="1" colspan="1">= Interleukin</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">MCP-1</td><td align="left" rowspan="1" colspan="1">= Monocyte chemoattractant protein-1</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">PIS</td><td align="left" rowspan="1" colspan="1">= Postimplantation syndrome</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">POD</td><td align="left" rowspan="1" colspan="1">= Postoperative day</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">SACP</td><td align="left" rowspan="1" colspan="1">= Selective antegrade cerebral perfusion</td></tr><tr style="background-color:#e6e7e8"><td align="left" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" rowspan="1" colspan="1">= Tumor necrosis factor alpha</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>The interleukin (IL) family is a group of cytokines involved in the pathogenesis of
inflammatory, allergic, infectious, immunodeficient, neoplastic, fibrotic, and
hypoxic disorders<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Of the cardiac surgical patients, those with
aortic dissection (AD) showed particular inherent relationships to IL-6<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Clinical research revealed, in
patients receiving an aortic aneurysm/dissection repair, that the circulating IL-6
levels differed between acute AD and hypertensive or healthy controls<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. However, there has been no report
comprehensively describing the profiles of circulating IL-6 levels in patients with
AD so far. In order to highlight the potential role of the circulating IL-6 in
patients with AD, a comprehensive review is conducted.</p></sec><sec sec-type="methods"><title>METHODS</title><p>PubMed and "<italic>Baidu</italic>" Scholar databases were carefully retrieved for
publications reporting on IL-6 in AD patients, published between 2000 and 2017. The
search terms included "interleukin-6", "aortic dissection", and
"circulating/serum/plasma/blood/cerebrospinal fluid". Bibliographic references were
also tracked down for the completeness of the literature retrieval.
Immunohistochemistry of IL-6 in AD patients were not included in this study.</p><p>Data were carefully extracted for details of the study population, demographics of
patients, type of AD, detection method and unit of IL-6, source of sampling,
circulating IL-6 values, and therapeutic interventions.</p><p>Quantitative data were presented as mean&#x000b1;standard deviation with range and
median values. The intergroup differences were compared by independent samples
<italic>t</italic>-test. <italic>P</italic>&#x0003c;0.05 was considered statistically
significant.</p></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patient Information</title><p>In total, 19 articles were collected<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r22" ref-type="bibr">22</xref>]</sup>. The study
group included 787 AD patients. In one (5.3%) of the reports, the study group
involved both acute and subacute AD cases, but the authors did not indicate the
patient number of different AD phases<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Therefore, the prevalence of acute and subacute AD
cases in the study groups could not be assessed. The control groups comprised
1,164 patients, including 543 AD patients (461 acute AD, 47 subacute AD, and 35
chronic AD patients), 260 hypertensive patients, and 361 healthy individuals
(<xref rid="t2" ref-type="table">Table 1</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; settings of the two groups.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" style="border-left:hidden" rowspan="1" colspan="1">Patients&#x02019; setting</th><th align="center" rowspan="1" colspan="1">Study Group</th><th align="center" style="border-right:hidden" rowspan="1" colspan="1">Control</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Aortic dissection</td><td align="center" rowspan="1" colspan="1">787 (100)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">543 (46.6)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type A</td><td align="center" rowspan="1" colspan="1">315 (40.0)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">191 (35.2)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type B</td><td align="center" rowspan="1" colspan="1">303 (38.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">305 (56.2)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type
unspecified</td><td align="center" rowspan="1" colspan="1">169 (21.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">47 (8.7)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">260 (22.3)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Healthy</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">361 (31.0)</td></tr></tbody></table></table-wrap><p>There was no significant difference in the patients&#x02019; ages between the study and
control groups (53.3&#x000b1;6.1 years <italic>vs. </italic>51.2&#x000b1;5.7
years, <italic>P</italic>=0.2702). In the study groups, there were 685 (72.6%)
male and 259 (27.4%) female patients with a male-to-female ratio of 2.64:1,
while in the control groups, there were 700 (69.9%) male and 301 (30.1%) female
patients with a male-to-female ratio of 2.33:1.</p><p>Apart from the observations on the surgical or endovascular treatment and adverse
events, such as acute lung injury (ALI)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>, postimplantation syndrome (PIS)<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, and death<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>, therapeutic interventions in
the study groups also included dexmedetomidine<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, 50% xenon<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, antithrombin<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>, deep hypothermic circulatory arrest (DHCA) with
selective antegrade cerebral perfusion (SACP)<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, ulinastatin<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, and <italic>Qishen Yiqi </italic>dripping
pill, a Chinese patent drug<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Most of the samples for IL-6 detection were drawn from the veins, especially from
the peripheral veins, while samples of a few patients were drawn from the artery
or cerebrospinal fluid (<xref rid="t3" ref-type="table">Table 2</xref>). In six
(31.6%) reports, the detection of IL-6 was not mentioned. Of the remaining 13
(68.4%) reports, IL-6 was detected by enzyme linked immunosorbent assay (ELISA)
in 12 (92.3%) reports<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r14" ref-type="bibr">14</xref>-<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r21" ref-type="bibr">21</xref>]</sup>, and in one (7.7%) report,
the detection method was not given, but an Immulite 2000 System Analyzer for
this purpose was described, instead<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. In 17 reports, the unit of IL-6 was pg/mL or
ng/L<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r15" ref-type="bibr">15</xref>-<xref rid="r21" ref-type="bibr">21</xref>]</sup>, whereas in
two reports, it was ug/L<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. The detection method of IL-6
in the latter two reports was not described.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 2</label><caption><p>Source of samples.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" style="border-left:hidden" rowspan="1" colspan="1">Source of sample</th><th align="center" rowspan="1" colspan="1">Study Group</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" style="border-right:hidden" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Vein</td><td align="center" rowspan="1" colspan="1">563 (95.1)</td><td align="center" rowspan="1" colspan="1">684 (95.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">1247 (95.8)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peripheral</td><td align="center" rowspan="1" colspan="1">294 (52.2)</td><td align="center" rowspan="1" colspan="1">363 (53.1)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">657 (52.7)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Central</td><td align="center" rowspan="1" colspan="1">113 (20.1)</td><td align="center" rowspan="1" colspan="1">119 (17.4)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">232 (18.6)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unspecified</td><td align="center" rowspan="1" colspan="1">156 (27.7)</td><td align="center" rowspan="1" colspan="1">202 (29.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">358 (28.7)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Artery</td><td align="center" rowspan="1" colspan="1">&#x000a0;20 (3.3)</td><td align="center" rowspan="1" colspan="1">20 (2.8)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">40 (3.1)</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Cerebrospinal fluid</td><td align="center" rowspan="1" colspan="1">&#x000a0;9 (1.5)</td><td align="center" rowspan="1" colspan="1">5 (0.7)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">14 (1.1)</td></tr></tbody></table></table-wrap></sec><sec><title>The Effect of Pathology before Treatment</title><p>Circulating IL-6 levels of acute type A AD were significantly higher than those
of the healthy control (<xref ref-type="fig" rid="f1">Figure 1A</xref>), and so
were other proinflammatory cytokines, such as IL-4 and tumor necrosis factor
alpha (TNF-&#x003b1;)<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Li
et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> reported that in
patients with AD, of either type A or type B, the IL-6 level was higher than in
the healthy control (<xref ref-type="fig" rid="f1">Figure 1B</xref>). Zhong et
al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> compared IL-6
levels between AD patients and hypertensive or healthy subjects. They noted that
AD patients had a much higher IL-6 level than the other two groups (<xref ref-type="fig" rid="f1">Figure 1C</xref>), whereas the sampling time was not
mentioned. Nevertheless, the treatment of choice was not mentioned. Yang and
Meng<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> found out
that type A AD patients had a much higher IL-6 level than the control patients
(<xref ref-type="fig" rid="f1">Figure 1D</xref>). However, the sampling time
broadly extended from one day to 14 days after the onset of AD, and the
treatment of choice was not stated at all in their report. The plasma
TNF-&#x003b1; and IL-6 levels were measured by Qin et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> and they showed that the IL-6
level was significantly higher in the AD group than in the other two groups
(175&#x000b1;38 <italic>vs</italic>. 50&#x000b1;8 <italic>vs</italic>. 50&#x000b1;7
pg/mL, <italic>P</italic>&#x0003c;0.05). A similar trend was also reported by Gu et
al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, who described
that the IL-6 level was significantly higher in patients with type A AD than in
those with uncontrolled hypertension (50.41&#x000b1;42.95 pg/mL
<italic>vs</italic>. 5.82&#x000b1;2.49 pg/mL, <italic>P</italic>&#x0003c;0.05) and
control groups (50.41&#x000b1;42.95 pg/mL <italic>vs</italic>. 4.42&#x000b1;2.12
pg/mL, <italic>P</italic>&#x0003c;0.05). A similar significant increase of the plasma
TNF-&#x003b1; level was found in type A AD patients. The time intervals to the
peak plasma levels of IL-6 and TNF-&#x003b1; were shorter than of the C-reactive
protein<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, indicating
that IL-6 and TNF-&#x003b1; were more sensitive than C-reactive protein. Wen et
al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> reported that
the IL-6 value was higher in patients with acute AD than in hypertensive
patients and healthy controls (10.98&#x000b1;2.38 <italic>vs</italic>.
3.79&#x000b1;1.56 <italic>vs</italic>. 3.32&#x000b1;1.60 pg/mL,
<italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="f1">Figure 1E</xref>). No
relationships were found between IL-6, C-reactive protein, TNF-&#x003b1;, matrix
metalloproteinase-9 concentrations, and type of AD. In their "Methods" section,
the authors described three sampling time points; however, in their "Results"
section, only one set of IL-6 values was reported, and, for this set, the
sampling time was not indicated. It was presumably the preoperative
value<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. The
deceased group of acute AD patients showed a higher plasma IL-6 level than the
survival patients (17.92&#x000b1;4.61 pg/mL <italic>vs</italic>.
12.59&#x000b1;2.53 pg/mL, <italic>P</italic>&#x0003c;0.001) (<xref ref-type="fig" rid="f1">Figure 1F</xref>), indicating that IL-6 could be a predictive
biomarker for mortality, and the cutoff value for the prediction of death should
be 18.36 pg/mL, with a sensitivity of 87.4% and a specificity of
70.8%<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>The interleukin-6 (IL-6) levels of patients with aortic dissection
(AD) in comparison to those of the controls: (A) IL-6 levels of
patients with acute type A AD were significantly higher than those
of healthy controls; (B) IL-6 levels of either type A or type B AD
patients were higher than those of healthy controls; (C) IL-6 levels
between AD patients and hypertensive or healthy subjects; (D)
patients with type A AD showed a much higher IL-6 level than
controls; (E) IL-6 values were higher in patients with acute aortic
dissection (AAD) than in hypertensive or healthy subjects; and (F)
deceased patients with AAD showed a higher plasma IL-6 level than
survival patients. CAD = chronic aortic dissection; HTN =
hypertension; POD = postoperative day.</p></caption><graphic xlink:href="rbccv-34-05-0596-g01"/></fig>
</p><p>Zhong et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> also reported
the dynamic changes of IL-6 in AD group patients. They observed that, with the
development of AD, IL-6 values increased gradually and reached a peak value on
days 1-2 after the onset, followed by a gradual decrease. The IL-6 value
recovered to normal range in two months (<xref ref-type="fig" rid="f2">Figure
2</xref>).</p><p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Dynamic changes of interleukin-6 (IL-6) value showed a gradual
increase and it reached a peak value on day 1-2 after the onset of
aortic dissection</p></caption><graphic xlink:href="rbccv-34-05-0596-g02"/></fig></p></sec><sec><title>The Effect of Conservative Treatment</title><p>According to the oxygen index (PaO<sub>2</sub>/FiO<sub>2</sub>) under static
oxygen inhalation, Huang et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> divided their patients with AD into two groups: the ALI
group (PaO<sub>2</sub>/FiO<sub>2</sub> &#x02264;200 mmHg) (<italic>n</italic>=26)
and the non-ALI group (PaO<sub>2</sub>/FiO<sub>2</sub> &#x0003e;200 mmHg)
(<italic>n</italic>=59). On admission, no difference was noted in IL-6
levels between the two groups. During the conservative treatment, IL-6 and IL-8
initially increased and peaked in 48 hours, and then decreased gradually. IL-6
levels were significantly higher in the ALI group than in the non-ALI group
(116.4&#x000b1;4.1 &#x000b5;g/L <italic>vs</italic>. 62.9&#x000b1;2.3 &#x000b5;g/L,
<italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="f3">Figure
3</xref>)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p><fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>The interleukin-6 (IL-6) levels were significantly higher in the
acute lung injury (ALI) group than in the non-ALI group. AD = aortic
dissection.</p></caption><graphic xlink:href="rbccv-34-05-0596-g03"/></fig></p></sec><sec><title>The Effect of Endovascular Aortic Repair</title><p>Guo et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> divided their 187
acute AD patients with ALI randomly into two groups according to treatment of
choice: 94 were treated endovascularly with a stent graft and 93 were treated
medically. In the endovascularly treated patients, the IL-6 level was lower than
in the medically treated patients (13&#x000b1;4 ng/L <italic>vs</italic>.
26&#x000b1;12 ng/L, <italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="f4">Figure 4A</xref>). Li et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> performed a similar study by dividing 60 patients with
acute type B AD with ALI randomly into two groups: the observation group (30
patients receiving conservative and endovascular treatments) and the control
group (30 patients receiving conservative treatment only). It showed that IL-6
levels did not differ before treatment, and the observation group showed a
significantly lower IL-6 level after treatment (time after treatment was not
described) than the control group (13.4&#x000b1;5 ng/L <italic>vs</italic>.
26.4&#x000b1;13 ng/L, <italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="f4">Figure 4B</xref>). The total effective rate of the observation group was
100% (30/30), higher than the 73.3% (22/30) of the control group<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Gorla et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> reported that PIS was diagnosed
in 15.8% of AD patients receiving endovascular aortic repair. The IL-6 levels
significantly increased in the PIS group, and peaked 24 hours after endovascular
aortic repair (<xref ref-type="fig" rid="f5">Figure 5</xref>)<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. For Debakey type III AD
patients after endovascular aortic repair, routine treatment (&#x003b2;-blockers,
sodium nitroprusside, non-dihydropyridine calcium channel blocker, and
angiotensin converting enzyme inhibitor) combined with <italic>Qishen
Yiqi</italic> pills can lower the serum levels of inflammatory cytokines,
including IL-6 (<xref ref-type="fig" rid="f6">Figure 6</xref>) and
TNF-&#x003b1;<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p><fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>The interleukin-6 (IL-6) level of aortic dissection patients with
acute lung injury: (A) IL-6 level of endovascularly treated patients
was lower than of the medically treated patients; and (B) IL-6 level
of endovascularly treated patients after treatment (time after
treatment was not described) was lower than of the medically treated
patients. No difference of IL-6 level was found between the groups
before treatment.</p></caption><graphic xlink:href="rbccv-34-05-0596-g04"/></fig>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>The interleukin-6 (IL-6) level was significantly higher in the
patients with postimplantation syndrome (PIS) group than in those
without it.</p></caption><graphic xlink:href="rbccv-34-05-0596-g05"/></fig>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Patients who received Qishen Yiqi pills had a significant lower serum
interleukin-6 (IL-6) level than those who received conventional
therapy.</p></caption><graphic xlink:href="rbccv-34-05-0596-g06"/></fig>
</p></sec><sec><title>The Effect of CPB and Heart Arrest or Selective Cerebral Perfusion</title><p>Differences were noted in IL-6 levels of the cerebrospinal fluid between
surgically treated AD patients under either sole DHCA or combined DHCA and SACP;
patients with DHCA showed higher IL-6 levels with double peaks during the
perioperative period, whereas patients with combined DHCA and SACP showed lower
IL-6 levels with a single early peak at the end of the operation (<xref ref-type="fig" rid="f7">Figure 7</xref>)<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p><fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Deep hypothermic circulatory arrest (DHCA) patients showed higher
levels of interleukin-6 (IL-6) with double peaks during the
perioperative period, whereas the combined DHCA and selective
antegrade cerebral perfusion (SACP) patients showed lower IL-6
levels with a single early peak at the end of the operation.
AD=aortic dissection.</p></caption><graphic xlink:href="rbccv-34-05-0596-g07"/></fig></p></sec><sec><title>The Effect of Drugs/Agents</title><p>A clinical observation demonstrated that the infusion of antithrombin (3000 U)
significantly inhibited the inflammatory situation, leading to a significantly
decrease in IL-6 level (<xref ref-type="fig" rid="f8">Figure
8A</xref>)<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. In
acute AD patients receiving total arch replacement administered with
dexmedetomidine during the perioperative period, the IL-6 values were
significantly lower than in those without dexmedetomidine use 4, 8, and 24 hours
after the operation (<xref ref-type="fig" rid="f8">Figure 8B</xref>)<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. A comparison of dynamic IL-6
levels of acute AD patients undergoing surgical treatment between those with or
without the use of ulinastatin revealed that the ulinastatin group showed a
stepwise reduction of IL-6 levels from the start of operation to 24 hours after
operation (<xref ref-type="fig" rid="f8">Figure 8C</xref>)<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p><fig id="f8" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>Impacts of drug therapies on interleukin-6 (IL-6) levels of aortic
dissection patients: (A) the infusion of antithrombin (3000 U)
significantly inhibited the inflammatory situation, leading to a
significantly decreased IL-6 level; (B) IL-6 values were
significantly lower than those without dexmedetomidine use 4, 8, and
24 hours after the operation; (C) a comparison of dynamic IL-6
levels of acute aortic dissection patients undergoing surgical
treatment between those with or without the use of ulinastatin. The
ulinastatin patients showed a stepwise reduction of IL-6 levels from
the start of operation to 24 hours after operation; and (D) patients
treated with xenon had higher levels of IL-6 compared to the control
group before surgery. h=hour; POD=postoperative day</p></caption><graphic xlink:href="rbccv-34-05-0596-g08"/></fig></p><p>Pulmonary static inflation with 50% xenon during cardiopulmonary bypass
attenuated the decreased oxygen index and increased the respiratory index values
at the end of operation for Stanford type A AD. Patients treated with xenon had
higher levels of IL-6 compared to the control group before surgery (<xref ref-type="fig" rid="f8">Figure 8D</xref>). In the second (postoperative 10
minutes to postoperative six hours) and third fractions (postoperative 6-24
hours), IL-6, IL-10, TNF-&#x003b1;, and thromboxane B<sub>2</sub> levels were
similar in both groups<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Sato et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> reported that a
67-year-old female patient was diagnosed with advanced stage lung adenocarcinoma
and she was started on chemotherapy with 3.6 mg of pegfilgrastim as primary
prophylaxis for neutropenia. The pegfilgrastim use led to the development of
thoracic aortitis and subsequent asymptomatic AD. The authors stated that the
elevated serum IL-6 level observed in this patient might be a cause of the
occurrence of aortic disorders. However, the authors did not mention the
subsequent management of the associated AD<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>As a result of blood test in AD patients, the elevations of IL-6, IL-8, and
granulocyte-colony stimulating factor were observed after the onset of AD,
therefore the mechanism of vascular inflammation after AD was common in a mouse
model of AD and in patients with acute AD, suggesting that the IL-8 receptor
antagonist (under development) and the anti-human IL-6 monoclonal antibody
preparation may be effective in preventing the complications and improving the
prognosis of patients with acute AD<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The significantly increased levels of the proinflammatory cytokines in acute AD
patients illustrated that the occurrence of AD was closely related to the
inflammatory condition and stress of the patient<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. IL-6 is a pyrogen and is in a close relation to
the constitutional symptom, such as fever, of AD patients. Plasma IL-6 reaches a
peak value within 1-2 hours after the onset of AD. It is hypothesized that there is
usually an uncontrolled hypertension at the initial stage of AD onset, and that IL-6
is also involved in the regulation of blood pressure<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. However, it is unclear that the significant
difference found in circulating IL-6 between hypertensive patients and healthy
individuals should be explained by the fact that the blood pressure of hypertensive
patients was not well controlled.</p><p>Guo et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> tried to explain the
associated ALI in AD patients. They proposed that the activation of inflammatory
cells and the release of inflammatory mediators might occur in acute AD patients.
The pulmonary function of the patients was therefore compromised, and it thus led to
ALI. Endovascular repair of AD could effectively control the inflammatory cytokines
and the aorta was well remodeled.</p><p>IL-6 is released by the vascular endothelium in the blood stream and stimulates the
liver to produce acute phase proteins, such as fibrinogen and C-reactive protein. In
a study involving 22 patients receiving endovascular aortic repair, the inflammatory
cascade is initiated by IL-6 release from aneurysmal thrombus formation, resulting
in the synthesis of TNF-&#x003b1;<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. IL-6 may play a pivotal role in the pathogenesis of PIS, which
represents a systemic inflammatory response syndrome initially observed following
endovascular aortic repair of infrarenal abdominal aortic aneurysms. All-cause
mortality occurred in 6.3% (7/112) of the non-PIS patients and in 0.0% (0/21) of the
PIS patients. The predictive value of IL-6 in the postoperative mortality was not
evaluated<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Cardiopulmonary bypass-induced leucocytosis and increased plasma IL-6 and
TNF-&#x003b1; values indicate an associated inflammatory response. Experimental
studies revealed that the systemic inflammatory response syndrome did not seem to be
provoked during DHCA and was mainly induced during reperfusion<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Clinical observations also
disclosed that the IL-6 level was much lower in DHCA patients than in patients with
low-flow cardiopulmonary bypass 0.5 and 2 hours after operation<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. SACP appeared to be superior to
hypothermic circulatory arrest alone in terms of neuroprotective effects<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. It allowed more complicated arch
repair procedures to be performed with a significantly longer cerebral exclusion
time without increasing the risks of stroke or death<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p><p>Ulinastatin can inhibit the release of the inflammatory cytokines and act as an
anti-inflammatory agent. During DHCA procedures, ulinastatin can decrease the
cytokine levels and improve the prognosis of the patients<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. As a highly selective
&#x003b1;<sub>2</sub>-adrenergic agonist, dexmedetomidine has analgesic, sedative,
antianxiety, stress-reducing, and sympathetic nerve activity-inhibiting effects. It
shows mild inhibition to respiration. In recent years, it has been widely used in
patients during the perioperative period. Dexmedetomidine could inhibit the
synthesis of the related inflammatory cytokines, such as TNF-&#x003b1;, IL-1, and
IL-6 by inhibiting the Toll-like receptor 4/nuclear factor-&#x003ba;B
signaling<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. The infusion
of antithrombin may prevent from further damage to the endothelial cells. In this
way, the release of the inflammatory cytokines and the adhesion molecules were well
controlled. It also demonstrated that the antithrombin possesses anti-inflammatory
and anti-cellular adhesion effects<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Pulmonary static inflation with 50% xenon during cardiopulmonary bypass decreased the
oxygen index and increased the respiratory index values at the end of surgery for
Stanford type A AD<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>The <italic>Qishen Yiqi</italic> dripping pill is made from the extracts with the
active ingredients of <italic>Radix Astragali, Radix Salviae Miltiorrhizae</italic>,
and <italic>Radix Notoginseng</italic> by modern pharmaceutical
technologies<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>.
<italic>Qishen Yiqi</italic> dripping pills have anti-inflammatory,
antifibrotic, free radical scavenging, lipid-lowering, atherosclerotic plaque
stabilizing, and tissue damage repairing effects. The inhibition of the inflammatory
factors and the reduction of the inflammatory responses were also confirmed by
clinical studies. Chen et al.<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>
applied the <italic>Qishen Yiqi</italic> dripping pills in patients with acute
myocardial infarction for 12 weeks and found out that the serum brain natriuretic
peptide, TNF-&#x003b1;, and IL-6 levels in the patients of the investigational
treatment group significantly decreased in comparison to those of patients of the
conventional treatment groups. It demonstrated that the <italic>Qishen Yiqi</italic>
dripping pills could reduce serum TNF-&#x003b1; and IL-6 levels. The mechanism of
action was considered to be related to the inhibition of inflammatory factors by the
<italic>Qishen Yiqi</italic> dripping pills<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. The Chinese medicine <italic>Qishen Yiqi</italic>
dripping pills could lower serum inflammatory factors through the promotion of
vascular endothelial cell repair, clearing the free radicals so as to enhance aortic
vascular regeneration<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>Neutropenia is a common complication of chemotherapy in cancer. Pegfilgrastim, a
granulocyte colony stimulating factor that stimulates bone marrow and promotes
growth of the neutrophils, is effective in reducing the incidence of infection
during chemotherapy associated with fever and neutropenia. Drug-induced aortitis
caused by pegfilgrastim observed by Sato et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> was associated with an extremely elevated IL-6 on day 13
(714 pg/mL), while aortitis was found on day 14, and Stanford type B AD was
incidentally found on day 36. The authors suggested a casual relation between
pegfilgrastim, IL-6, and AD.</p><p>It has been proved in a series of experimental studies the crucial roles that IL-6
plays in the development of AD. Ju et al.<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup> revealed that AD was triggered by IL-6 signaling pathway
and activator of transcription-3 via the Th17 lymphocyte-IL-17 axis. Sano and
Anzai<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup> proved that the
chemokine-dependent signaling caused neutrophilia and massive neutrophil
accumulation in the dissected aorta, thereby leading to aortic enlargement and
rupture via IL-6 production. Tieu et al.<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup> noted that inflammatory cytokines, including IL-6, were
seen mainly in the tunica adventitia with local monocyte recruitment and activation,
thereby promoting monocyte chemoattractant protein-1 (MCP-1) secretion, vascular
inflammation, extracellular matrix degradation, and aortic destabilization.
Moreover, activation of IL-6-signal transducer and activator of transcription 3
signaling was found to be responsible for the aneurysmal dilation in mgR/mgR mice
through aggravating extracellular matrix degradation due to an upregulated matrix
metalloproteinase-9<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>.
It has been therefore proposed IL-6 neutralization as novel therapeutic strategies
to prevent development of aneurysmal formation and rupture in patients with acute
AD<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>AD is an inflammatory process with an elevated IL-6 level in comparison to
hypertensive or healthy controls. Adverse events, such as ALI, PIS, and death, are
associated with an elevated IL-6 level. Therapeutic interventions, such as
antithrombin, dexmedetomidine, ulinastatin, 50% xenon, and the <italic>Qishen
Yiq</italic>i dripping pill, aiming at attenuating the inflammatory status can
significantly decrease the IL-6 level. Endovascular aortic repair can effectively
control the inflammatory cytokines. SACP with DHCA during aortic arch replacement
shows better neuroprotective effect with an improved IL-6 level of the cerebrospinal
fluid. The present study proved that circulating IL-6 could be a reliable biomarker
for the diagnosis of AD and for the evaluation of the therapeutic outcomes and the
prognosis of AD patients. Therapeutic interventions aiming at attenuating the
inflammatory status by IL-6 neutralization could effectively decrease the IL-6 level
and thus reverse the progression of the disorder of AD patient.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" style="border-left:hidden" colspan="2" rowspan="1">Author's roles
&#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SMY</td><td align="left" rowspan="1" colspan="1">Conception or design of the work; or the acquisition,
<break/> analysis, or interpretation of data for the work; drafting
<break/> the work or revising it critically for important
intellectual <break/> content; final approval of the version to be
published <break/></td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="supported-by"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>SM</given-names></name><name><surname>Yan</surname><given-names>SL</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name></person-group><article-title>Unusual aspects of cardiac myxoma</article-title><source>Anatol J Cardiol</source><year>2017</year><volume>17</volume><issue>3</issue><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.14744/AnatolJCardiol.2017.7557</pub-id><pub-id pub-id-type="pmid">28321109</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushnell</surname><given-names>JR</given-names></name><name><surname>Weston</surname><given-names>C</given-names></name><name><surname>Karamadoukis</surname><given-names>L</given-names></name></person-group><article-title>An unusual presentation of atrial myxoma with haematuria and
proteinuria</article-title><source>NDT Plus</source><year>2011</year><volume>4</volume><issue>2</issue><fpage>124</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1093/ndtplus/sfq204</pub-id><pub-id pub-id-type="pmid">25984131</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>HZ</given-names></name></person-group><article-title>Interleukin-6 in cardiac surgery</article-title><source>Period Biol</source><year>2017</year><volume>119</volume><issue>2</issue><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.18054/pb.v119i2.4928</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>RP</given-names></name><name><surname>Cheng</surname><given-names>JL</given-names></name><name><surname>Dong</surname><given-names>TL</given-names></name></person-group><article-title>Effects of dexmedetomidine on inflammatory factors in patients
undergoing aortic arch replacement with cardiopulmonary
bypass</article-title><source>J Zhengzhou Univ (Med Sci)</source><year>2016</year><volume>51</volume><issue>3</issue><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.13705/j.issn.1671-6825.2016.03.034</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorla</surname><given-names>R</given-names></name><name><surname>Erbel</surname><given-names>R</given-names></name><name><surname>Kahlert</surname><given-names>P</given-names></name><name><surname>Tsagakis</surname><given-names>K</given-names></name><name><surname>Jakob</surname><given-names>H</given-names></name><name><surname>Mahabadi</surname><given-names>AA</given-names></name></person-group><article-title>Clinical features and prognostic value of stent-graft-induced
post-implantation syndrome after thoracic endovascular aortic repair in
patients with type B acute aortic syndromes</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><issue>4</issue><fpage>1239</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezv355</pub-id><pub-id pub-id-type="pmid">26487101</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>HW</given-names></name><name><surname>Xiao</surname><given-names>ZH</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>MH</given-names></name></person-group><article-title>Time-dependent changes of plasma inflammatory biomarkers in type
A aortic dissection patients without optimal medical
management</article-title><source>J Cardiothorac Surg</source><year>2015</year><volume>10</volume><fpage>3</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1186/s13019-014-0199-0</pub-id><pub-id pub-id-type="pmid">25592634</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>ZX</given-names></name><name><surname>Yao</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>T</given-names></name></person-group><article-title>Influence of thoracic endovascular aortic repair on inflammatory
cell factors in patients with acute aortic dissection rupture lung
damage</article-title><source>Chin J Mod Drug Appl</source><year>2017</year><volume>11</volume><issue>3</issue><fpage>51</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1006-2084.2016.09.057</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>KK</given-names></name></person-group><article-title>Variation of interleukin-6, interleukin-8 in serum of patients
with acute type A aortic dissection, and its relationship with acute lung
injury</article-title><source>Chin J Thorac Cardiovasc Surg</source><year>2016</year><volume>32</volume><issue>11</issue><fpage>665</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-4497.2016.11.006</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name></person-group><article-title>Effects of pulmonary static inflation with 50% xenon on oxygen
impairment during cardiopulmonary bypass for Stanford type A acute aortic
dissection a pilot study</article-title><source>Medicine (Baltimore)</source><year>2017</year><volume>96</volume><issue>10</issue><elocation-id>e6253</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000006253</pub-id><pub-id pub-id-type="pmid">28272227</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>DF</given-names></name><name><surname>Dong</surname><given-names>QL</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name></person-group><article-title>Effects of antithrombin on inflammatory cytokines and adhesion
molecules in Stanford B aortic stent graft implantation</article-title><source>J Chin Physician</source><year>2013</year><volume>15</volume><issue>6</issue><fpage>837</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.3870/yydb.2012.11.021</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Ni</surname><given-names>LC</given-names></name><name><surname>Li</surname><given-names>QC</given-names></name><name><surname>Ma</surname><given-names>LM</given-names></name></person-group><article-title>The effect of thoracic aortic endovascular repair of acute aortic
dissection ruptured lung injury and inflammatory cytokines</article-title><source>Med Recapit</source><year>2016</year><volume>22</volume><issue>9</issue><fpage>1851</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1006-2084.2016.09.057</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>XD</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>FX</given-names></name><name><surname>Yao</surname><given-names>JM</given-names></name></person-group><article-title>Practical significance of D-dimer in the diagnosis of acute
aortic dissection Stanford type A</article-title><source>Chin J Esth Med</source><year>2012</year><volume>21</volume><issue>1</issue><fpage>89</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1008-6455.2012.z1.071</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>LZ</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>WP</given-names></name><name><surname>Zhao</surname><given-names>XQ</given-names></name></person-group><article-title>Release of S100&#x000df; and IL-6 into cerebrospinal fluid after
aortic operation assisted by two different cerebral protective
methods</article-title><source>Zhonghua Wai Ke Za Zhi [Internet]</source><year>2007</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>45</volume><issue>22</issue><fpage>1561</fpage><lpage>1564</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/18282396">https://www.ncbi.nlm.nih.gov/pubmed/18282396</ext-link></comment><comment>Chinese</comment></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>PR</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>WP</given-names></name><name><surname>Sun</surname><given-names>LZ</given-names></name></person-group><article-title>Effect of early intervention with ulinastatin on inflammatory
cytokines in patients with Stanford A acute aortic dissection during
perioperative period</article-title><source>China Med</source><year>2017</year><volume>12</volume><issue>4</issue><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1673-4777.2017.04.010</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Potential mechanism of post-acute aortic dissection inflammatory
responses the role of mtDNA from activated platelets</article-title><source>Cardiology</source><year>2016</year><volume>135</volume><issue>4</issue><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1159/000446870</pub-id><pub-id pub-id-type="pmid">27529482</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>HJ</given-names></name><name><surname>Zhu</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Yang</surname><given-names>YN</given-names></name></person-group><article-title>Predictive value of interleukin-6 for mortality in patients with
acute aortic dissection</article-title><source>Chin J Clinicians (Electron Ed)</source><year>2015</year><volume>9</volume><issue>17</issue><fpage>3184</fpage><lpage>3187</lpage><pub-id pub-id-type="doi">10.3877/cma.j.issn.1674-0785.2015.17.008</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Kaji</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Tomii</surname><given-names>K</given-names></name></person-group><article-title>Thoracic aortitis and aortic dissection following pegfilgrastim
administration</article-title><source>Eur J Cardiothorac Surg</source><year>2017</year><volume>52</volume><issue>5</issue><fpage>993</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezx165</pub-id><pub-id pub-id-type="pmid">28549110</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>XL</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>LG</given-names></name></person-group><article-title>Plasma concentrations of interleukin-6, C-reactive protein, tumor
necrosis factor-a and matrix metalloproteinase-9 in aortic
dissection</article-title><source>Clin Chim Acta</source><year>2012</year><volume>413</volume><issue>1-2</issue><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2011.09.029</pub-id><pub-id pub-id-type="pmid">22001516</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>YW</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>QT</given-names></name></person-group><article-title>Comparison of plasma pro-inflammatory cytokine expressions in
patients with different types of acute aortic dissection</article-title><source>Chin Crit Care Med</source><year>2014</year><volume>26</volume><issue>10</issue><fpage>740</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.2095-4352.2014.10.014</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name></person-group><article-title>Intestinal barrier dysfunction a novel therapeutic target for
inflammatory response in acute Stanford type A aortic
dissection</article-title><source>J Chengdu Med Coll</source><year>2016</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1674-2257.2016.01.001</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>MH</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>EY</given-names></name></person-group><article-title>Clinical significances of plasma interleukin-6, C-reaction
protein and tumor necrosis factor-a in patients with aortic
dissection</article-title><source>Sichuan Da Xue Xue Bao Yi Xue Ban [Internet]</source><year>2015</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>46</volume><issue>2</issue><fpage>234</fpage><lpage>237</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25924436">https://www.ncbi.nlm.nih.gov/pubmed/25924436</ext-link></comment><comment>Chinese</comment></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="thesis"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name></person-group><source>Influence of "Qishen Yiqi Droplet" on inflammatory reaction in Debakey
type III aortic dissection patients after thoracic endovascular aneurysm
repair</source><comment>Master degree thesis of Guangzhou University of Chinese
Medicine</comment><year>2015</year><comment>Tutor: Zhu YH</comment><pub-id pub-id-type="doi">10.13359/j.cnki.gzxbtcm.2018.06.005</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagl</surname><given-names>C</given-names></name><name><surname>Khaladj</surname><given-names>N</given-names></name><name><surname>Peterss</surname><given-names>S</given-names></name><name><surname>Hoeffler</surname><given-names>K</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name><name><surname>Karck</surname><given-names>M</given-names></name></person-group><article-title>Hypothermic circulatory arrest with and without cold selective
antegrade cerebral perfusion impact on neurological recovery and tissue
metabolism in an acute porcine model</article-title><source>Eur J Cardiothorac Surg</source><year>2004</year><volume>26</volume><issue>1</issue><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2004.04.002</pub-id><pub-id pub-id-type="pmid">15200982</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Anzai</surname><given-names>J</given-names></name></person-group><article-title>The molecular mechanisms contributing to the pathophysiology of
systemic inflammatory response after acute aortic dissection</article-title><source>Nihon Rinsho Meneki Gakkai Kaishi</source><year>2016</year><volume>39</volume><issue>2</issue><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2177/jsci.39.91</pub-id><pub-id pub-id-type="pmid">27212594</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>M</given-names></name><name><surname>Bilgic</surname><given-names>E</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Vasquez</surname><given-names>E</given-names></name><name><surname>Wollschl&#x000e4;ger</surname><given-names>L</given-names></name><name><surname>Steinbrenner</surname><given-names>H</given-names></name></person-group><article-title>A cardiopulmonary bypass with deep hypothermic circulatory arrest
rat model for the investigation of the systemic inflammation response and
induced organ damage</article-title><source>J Inflamm (Lond)</source><year>2014</year><volume>11</volume><fpage>26</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1186/s12950-014-0026-3</pub-id><pub-id pub-id-type="pmid">25400510</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassani</surname><given-names>P</given-names></name><name><surname>Barankay</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>F</given-names></name><name><surname>Paek</surname><given-names>SU</given-names></name><name><surname>Heilmaier</surname><given-names>M</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name></person-group><article-title>Cardiac surgery with deep hypothermic circulatory arrest produces
less systemic inflammatory response than low-flow cardiopulmonary bypass in
newborns</article-title><source>J Thorac Cardiovasc Surg</source><year>2002</year><volume>123</volume><issue>4</issue><fpage>648</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1067/mtc.2002.121285</pub-id><pub-id pub-id-type="pmid">11986591</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matalanis</surname><given-names>G</given-names></name><name><surname>Hata</surname><given-names>M</given-names></name><name><surname>Buxton</surname><given-names>BF</given-names></name></person-group><article-title>A retrospective comparative study of deep hypothermic circulatory
arrest, retrograde, and antegrade cerebral perfusion in aortic arch
surgery</article-title><source>Ann Thorac Cardiovasc Surg [Internet]</source><year>2003</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>9</volume><issue>3</issue><fpage>174</fpage><lpage>179</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.atcs.jp/pdf/2003_9_3/174.pdf">http://www.atcs.jp/pdf/2003_9_3/174.pdf</ext-link></comment></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HP</given-names></name><name><surname>Nian</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>ZH</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name></person-group><article-title>Clinical research progress on Qishen Yiqi Dripping
Pill</article-title><source>J Liaoning Univ TCM</source><year>2013</year><volume>15</volume><issue>8</issue><fpage>84</fpage><lpage>86</lpage></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TG</given-names></name><name><surname>Ma</surname><given-names>ZQ</given-names></name><name><surname>Zhong</surname><given-names>ZY</given-names></name><name><surname>Sun</surname><given-names>GF</given-names></name><name><surname>Zhou</surname><given-names>YX</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Affect on heart function and serum cytokines in the patients
after acute myocardial infarct with compound Qishenyiqi dripping
pills</article-title><source>Jiangxi Med J</source><year>2011</year><volume>46</volume><issue>8</issue><fpage>687</fpage><lpage>689</lpage></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>X</given-names></name><name><surname>Ijaz</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Lejeune</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>Interleukin-6-signal transducer and activator of transcription-3
signaling mediates aortic dissections induced by angiotensin II via the
T-helper lymphocyte 17-interleukin 17 axis in C57BL/6 mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2013</year><volume>33</volume><issue>7</issue><fpage>1612</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.112.301049</pub-id><pub-id pub-id-type="pmid">23685554</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Anzai</surname><given-names>J</given-names></name></person-group><article-title>The molecular mechanisms contributing to the pathophysiology of
systemic inflammatory response after acute aortic dissection</article-title><source>Nihon Rinsho Meneki Gakkai Kaishi</source><year>2016</year><volume>39</volume><issue>2</issue><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2177/jsci.39.91</pub-id><pub-id pub-id-type="pmid">27212594</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tieu</surname><given-names>BC</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Lejeune</surname><given-names>W</given-names></name><name><surname>Recinos</surname><given-names>A 3rd</given-names></name><name><surname>Ju</surname><given-names>X</given-names></name></person-group><article-title>An adventitial IL-6/MCP1 amplification loop accelerates
macrophage-mediated vascular inflammation leading to aortic dissection in
mice</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>12</issue><fpage>3637</fpage><lpage>3651</lpage><pub-id pub-id-type="doi">10.1172/JCI38308</pub-id><pub-id pub-id-type="pmid">19920349</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>X</given-names></name><name><surname>Ijaz</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Lejeune</surname><given-names>W</given-names></name><name><surname>Vargas</surname><given-names>G</given-names></name><name><surname>Shilagard</surname><given-names>T</given-names></name></person-group><article-title>IL-6 regulates extracellular matrix remodeling associated with
aortic dilation in a fibrillin-1 hypomorphic mgR/mgR mouse model of severe
Marfan syndrome</article-title><source>J Am Heart Assoc</source><year>2014</year><volume>3</volume><issue>1</issue><elocation-id>e000476</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.113.000476</pub-id><pub-id pub-id-type="pmid">24449804</pub-id></element-citation></ref></ref-list></back></article>